Developing the Next Generation of Dermatology Treatments

Incyte’s science-first approach and heritage in immunology has formed the foundation of our company. Today, we are building on this legacy as we discover and develop innovative dermatology treatments to bring solutions to patients in need.

NAVIGATE TO
Resources

Our research and development efforts in dermatology are initially focused on a number of immune-mediated dermatologic conditions with a high unmet medical need, including atopic dermatitis, vitiligo and hidradenitis suppurativa.

We strive to identify and develop therapies to modulate immune pathways driving uncontrolled inflammation to help restore normal immune function and bring the body closer to homeostasis.

Resources

FOR HEALTHCARE PROFESSIONALS

Uncover Vitiligo

The European site on Vitiligo helps to provide Italian clinicians more information on Vitiligo.

Learn More from Uncover Vitiligo
Global Medical Information

Incyte is committed to providing timely and accurate product information to healthcare professionals upon request. If you need medical information or have a medical question, please visit incyteglobalmedicalinformation.com.

Medical Information and Adverse Reactions

To request medical information or report adverse reactions, send an email to eumedinfo@incyte.com or call +39 02.36049221/+800 00027423 (available 24 hours a day).

Disease Areas of Interest

VITILIGO

Vitiligo is a condition that causes the skin to lose its pigment cells (melanocytes), often resulting in discolored patches of the skin.

Vitiligo is a chronic autoimmune disease characterized by depigmentation of skin that results from the loss of pigment-producing cells known as melanocytes. Overactivity of the JAK signaling pathway is believed to drive inflammation involved in the pathogenesis and progression of vitiligo. It affects approximately 0.5% to 2.0% of the population globally1. In the United States, more than 1.5 million people are diagnosed with vitiligo2. The overall prevalence of the condition is estimated to be approximately 2–3 million3, with the majority of patients (approximately 85%) suffering from nonsegmental vitiligo4. Vitiligo can occur at any age, although many patients with vitiligo will experience initial onset before the age of 305. Vitiligo is associated with quality-of-life impairments6,7 and patients are at an increased risk for comorbidities and mental health disorders, including depression8,9.

References: 

  1. Kruger C, Schallreuter KU. A review of the worldwide prevalence of vitiligo in children/adolescents and adults. Int J Dermatol. 2012;51(10):1206-1212.
  2. Bergqvist C, Ezzedine K. Vitiligo: A Review. Dermatology. 2020;236:571-592.
  3. Gandhi K, Ezzedine K, Anastassopoulos KP, et al. Prevalence of vitiligo among adults in the United States. JAMA Dermatol. 2022;158(1):43-50.
  4. Ezzedine K, Eleftheriadou V, Whitton M, van Geel N. Seminar: Vitiligo. Lancet. 2015;386:74-84.
  5. Frisoli M, Essien K, Harris JE. Vitiligo: mechanisms of pathogenesis and treatment. Annu Rev Immunol. 2020;38(1):621-648.
  6. Morrison B, Burden-Teh E, Batchelor JM, Mead E, Grindlay D, Ratib S. Quality of life in people with vitiligo: a systematic review and meta-analysis. Br J Dermatol. 2017;177(6):e338-e339.
  7. Silverberg JI, Silverberg NB. Association between vitiligo extent and distribution and quality-of-life impairment. JAMA Dermatol. 2013;149(2):159-164.
  8. Wang G, Qiu D, Yang H, Liu W. The prevalence and odds of depression in patients with vitiligo: a meta-analysis. J Eur Acad Dermatol Venereol. 2018;32(8):1343-1351.
  9. Alavi A, Hamzavi I, Brown K, et al. Janus kinase 1 inhibitor INCB054707 for patients with moderate-to-severe hidradenitis suppurativa: results from two phase II studies. Br J Dermatol. 2022;186(5):803-813. doi:10.1111/bjd.20969

ATOPIC DERMATITIS

Atopic dermatitis (AD)—the most common type of eczema—is an immune-mediated skin condition that causes irritation and itch.

Atopic dermatitis (AD) is a common chronic disease characterized by inflammation of the skin. Signs and symptoms of AD include irritated and itchy skin that can cause red lesions that may ooze and crust1. Patients with AD are also more susceptible to bacterial, viral and fungal infections2. The clinical signs and symptoms of the disease can have a profound impact on a patient’s quality of life3-8.

References: 

  1. American Academy of Dermatology Association. Eczema Types: Atopic Dermatitis Symptoms. https://www.aad.org/public/diseases/eczema/types/atopic-dermatitis/symptoms. Accessed on September 11, 2020.
  2. Baker BS. Clin Exp Immunol. 2006;144(1):1-9.
  3. Eichenfield LF, Tom WL, Berger TJ, et al. J Am Acad Dermatol. 2014;71(1):116-132.
  4. Boguniewicz M, Fonacier L, Guttman-Yassky E, Ong PY, Silverberg J, Farrar JR. Ann Allergy Asthma Immunol. 2018;120:10-22.
  5. Narla S, Silverberg JI. Ann Allergy Asthma Immunol. 2018;120(1):66-72.
  6. Silverberg JI, Gelfand JM, Margolis DJ, et al. Ann Allergy Asthma Immunol. 2018;121(3):340-347.
  7. Silverberg JI, Gelfand JM, Margolis DJ, et al. Br J Dermatol. 2019;181(3):554-565.
  8. Silverberg JI, Garg NK, Paller AS, Fishbein AB, Zee PC. J Invest Dermatol. 2015;135(1):56-66.

HIDRADENITIS SUPPURATIVA

Red, painful lumps can develop under the skin for many reasons—including a condition called hidradenitis suppurativa.

Hidradenitis suppurativa, also known as acne inversa, is an inflammatory skin condition that causes painful bumps to form in the armpit, groin, breast and anal regions of the body1. The condition typically begins during puberty and is often most active between the ages of 20 and 40 years. Some of the bumps can eventually lead to disfiguring scars. It has a significant impact on daily life and can be debilitating for some patients1.

Reference: 

  1. Morrison B, Burden-Teh E, Batchelor JM, Mead E, Grindlay D, Ratib S. Br J Dermatol. 2017;177(6):e338-e339.